JP2019519770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519770A5 JP2019519770A5 JP2018562324A JP2018562324A JP2019519770A5 JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5 JP 2018562324 A JP2018562324 A JP 2018562324A JP 2018562324 A JP2018562324 A JP 2018562324A JP 2019519770 A5 JP2019519770 A5 JP 2019519770A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- biomarker
- sequence
- peripheral
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022072884A JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| EP16171885.3 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072884A Division JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519770A JP2019519770A (ja) | 2019-07-11 |
| JP2019519770A5 true JP2019519770A5 (enExample) | 2020-07-16 |
| JP7066639B2 JP7066639B2 (ja) | 2022-05-13 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562324A Active JP7066639B2 (ja) | 2016-05-30 | 2017-05-30 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
| JP2022072884A Active JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072884A Active JP7511806B2 (ja) | 2016-05-30 | 2022-04-27 | 患者における抗ｃｄ１９治療の治療的有用性を予測するための方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (enExample) |
| EP (2) | EP3465214B1 (enExample) |
| JP (2) | JP7066639B2 (enExample) |
| KR (1) | KR102416144B1 (enExample) |
| CN (2) | CN115932265B (enExample) |
| AU (1) | AU2017272608B2 (enExample) |
| CY (1) | CY1124768T1 (enExample) |
| DK (2) | DK3465214T3 (enExample) |
| EA (1) | EA201892542A1 (enExample) |
| ES (2) | ES2981046T3 (enExample) |
| FI (1) | FI3916392T3 (enExample) |
| HR (2) | HRP20210938T1 (enExample) |
| HU (2) | HUE054860T2 (enExample) |
| IL (1) | IL263103B2 (enExample) |
| LT (2) | LT3465214T (enExample) |
| MA (2) | MA45124B1 (enExample) |
| MD (2) | MD3465214T2 (enExample) |
| MX (2) | MX388502B (enExample) |
| PL (2) | PL3465214T3 (enExample) |
| PT (2) | PT3465214T (enExample) |
| RS (2) | RS62155B1 (enExample) |
| SG (2) | SG10201911958SA (enExample) |
| SI (2) | SI3916392T1 (enExample) |
| SM (2) | SMT202100291T1 (enExample) |
| WO (1) | WO2017207574A1 (enExample) |
| ZA (2) | ZA201808647B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| WO2021084062A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| TW202131950A (zh) * | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| EP4168449A1 (en) * | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| AU2021391623A1 (en) * | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| WO2026024668A1 (en) * | 2024-07-22 | 2026-01-29 | Abbott Laboratories | Method of determining a volume of a liquid in a sample |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| PT1853718E (pt) * | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20100167315A1 (en) | 2006-09-13 | 2010-07-01 | Glycode | Method for investigating the response to a treatment with a monoclonal antibody |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| SG190254A1 (en) | 2010-11-15 | 2013-06-28 | Medimmune Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| CA2841738C (en) * | 2011-08-16 | 2022-12-06 | Morphosys Ag | Combination therapy with an anti-cd19 antibody and a purine analog |
| SG10201606785UA (en) | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| EP2791165A4 (en) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY |
| US20130273032A1 (en) | 2012-03-02 | 2013-10-17 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| US10969391B2 (en) | 2014-07-11 | 2021-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
| JP6916741B2 (ja) | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| SMT202100317T1 (it) | 2016-06-27 | 2021-07-12 | Morphosys Ag | Formulazioni di anticorpi anti-cd19 |
| WO2018078123A1 (en) | 2016-10-28 | 2018-05-03 | Morphosys Ag | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| HUE063119T2 (hu) | 2017-05-31 | 2024-01-28 | Morphosys Ag | Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
| LT4051710T (lt) | 2019-10-31 | 2026-03-10 | Incyte Corporation | Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles |
| TW202131950A (zh) | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗ｃｄ１９療法 |
| WO2021084062A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| EP4168449A1 (en) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| AU2021391623A1 (en) | 2020-12-04 | 2023-06-29 | Incyte Corporation | Anti-cd19 combination therapy |
| US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
-
2017
- 2017-05-30 ES ES21170716T patent/ES2981046T3/es active Active
- 2017-05-30 SM SM20210291T patent/SMT202100291T1/it unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en not_active Ceased
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2017-05-30 SI SI201731527T patent/SI3916392T1/sl unknown
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 PL PL21170716.1T patent/PL3916392T3/pl unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 MD MDE20220770T patent/MD3916392T2/ro unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265B/zh active Active
- 2017-05-30 MX MX2018014702A patent/MX388502B/es unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 HR HRP20240670TT patent/HRP20240670T1/hr unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 SM SM20240204T patent/SMT202400204T1/it unknown
- 2017-05-30 HU HUE21170716A patent/HUE067450T2/hu unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active Active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-01-15 ZA ZA2021/00296A patent/ZA202100296B/en unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US12631639B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023093495A5 (enExample) | ||
| Barnes et al. | Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis | |
| FI3916392T3 (fi) | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla | |
| Withers et al. | Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells | |
| Roufosse et al. | Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome | |
| JP2022002520A5 (enExample) | ||
| Gianni et al. | Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) | |
| JP2022119854A5 (enExample) | ||
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| JP2013542194A5 (enExample) | ||
| JP2021523213A5 (enExample) | ||
| Intongkam et al. | Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| RU2018107929A (ru) | Комбинации и их использование | |
| JP2018021031A5 (enExample) | ||
| FI3699198T3 (fi) | Menetelmiä kasvaimen hoitoon bispesifistä CD3XCD20-vasta-ainetta käyttämällä | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| JP2022532519A5 (enExample) | ||
| JP2012519707A5 (enExample) | ||
| JP2019517485A5 (enExample) | ||
| Verschoor et al. | MicroRNA-155 is required for clearance of Streptococcus pneumoniae from the nasopharynx | |
| JP2022554324A5 (enExample) | ||
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof |